曲美他嗪对慢性心力衰竭患者血清CA125、IL-6及BNP的作用被引量：3

Effect of trimetazidine on levels of serum CA125, IL-6, and BNP in patients with chronic heart failure

在线阅读下载PDF

导出

摘要目的观察曲美他嗪对慢性心力衰竭（CHF）患者血清CAl25、IL-6及BNP的影响，探讨曲美他嗪治疗CHF的临床疗效。方法选取本院2012年9月至2015年9月收治的CHF患者160例，随机分为对照组及观察组，各80例。对照组予以标准的CHF药物治疗，观察组在标准CHF药物治疗基础上联合曲美他嗪治疗，疗程3个月。观察治疗前后症状的改善情况，根据纽约心功能（NYHA）分级进行疗效评价，并检测血清糖类抗原125（CA125）、白介素-6（IL-6）及B型钠尿肽（BNP）的表达变化。结果治疗前两组患者年龄、性别及心功能分级，差异无统计学意义（t=-0．272，P=0．786；x2=0．223，P=0．633；x2=0．503，P=0．778）。观察组临床疗效总有效率90．0％，明显优于对照组的81．3％（x2=7．047，P=0．030）。两组治疗后血清CA125、IL-6及BNP的表达均下调（P〈0．001），观察组血清CA125、IL-6及BNP表达较对照组明显下降（t=5．270、8．960、10．523，P〈0．001）。结论曲美他嗪治疗CHF疗效显著，可显著改善患者NYHA分级，并能降低血清CA125、IL-6及BNP的表达。

作者刘悦香

机构地区胶州市人民医院南院内二科

出处《国际医药卫生导报》 2016年第8期1106-1108,共3页 International Medicine and Health Guidance News

关键词曲美他嗪慢性心力衰竭糖类抗原125 白介素-6 B型钠尿肽

分类号 R541.61 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献13

1谢瑞芹,都军,郝玉明,崔炜,刘凡,祖秀光.曲美他嗪治疗冠心病心力衰竭疗效观察[J].中华心血管病杂志,2004,32(1):77-77. 被引量：72
2陈亚南,王岚峰.心力衰竭相关生物学标记物的研究近况[J].中华老年心脑血管病杂志,2012,14(2):211-213. 被引量：12
3谢进,李欣,胡钢,许臣洪,胡沛.卡维地洛联合缬沙坦治疗慢性心力衰竭的临床效果及安全性[J].中国老年学杂志,2012,32(7):1352-1353. 被引量：58
4Tang ASL, Wells GA, Talagic M, et al. Cardiac resynchronization therapy for mild-to-moderate heart failure[J]. N Engl J Med, 2010, 363(25): 2385-2395.
5Howard PA, Shireman TI. Heart failure drug utilization patterns for Medicaid patients before and after a heart failure-related hospitalization[J]. Congest Heart Fail, 2005, 11(3): 124-128.
6Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure[J]. J Coll Cardiol, 2012, 59(10): 913-922.
7曾纪羡.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效分析[J].国际医药卫生导报,2014,20(5):675-677. 被引量：37
8梁丽萍,潘勇翔,陈虹,陈毓青,王志成,易玉芳.盐酸曲美他嗪对慢性心力衰竭患者心功能及血清基质金属蛋白酶-9的影响[J].广西医科大学学报,2013,30(6):919-920. 被引量：5
9郝冬琴,宋付凯,韩文杰,刘恒亮,赵友民.曲美他嗪联合瑞舒伐他汀治疗缺血性心肌病心力衰竭的疗效[J].中国老年学杂志,2012,32(15):3152-3153. 被引量：48
10彭澍,吴平生,毛琛.曲美他嗪治疗慢性心力衰竭随机对照研究的Meta分析[J].循证医学,2011,11(4):239-243. 被引量：5

二级参考文献103

1夏华玲,李迎春,黄中云.缬沙坦治疗慢性心力衰竭疗效观察[J].临床医学,2006,26(3):36-37. 被引量：13
2陆弋,陈样新,方崇峰,江建军,唐礼江.血清糖类抗原125及血浆尿钠肽水平与充血性心力衰竭的关系[J].临床心血管病杂志,2007,23(8):582-584. 被引量：12
3Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options [J]. J Am Coll Cardiol, 2008,51 ( 2 ) : 93-102.
4Kantor PF, Lucien A, Kozak R, et al. The antianginal drug Trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase [J]. Circ Res, 2000,86 (5) :580-588.
5Lopaschuk GD, Barr R, Thomas PD, et al. Beneficial effects of Trimetazidine in ex vivo working ischemic heart are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase [J]. Circ Res, 2003,93 (3) : e26-e32.
6Maclnnes A, fairman DA, Binding P, et al. The antianginal Trimetazidine does not exert its functional benefit via inhibition of long-chain 3-ketoacyl coenzyme A thiolase [J]. Circ Res, 2003,93(3) :e33-e37.
7Daniel G, Kramer MD, Thomas A, et al. Quantitive evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction [J]. J Am Col Cardiol, 2010,56 ( 5 ) : 392-406.
8Gunes Y, Guntekin U, Tuncer M, et al. Improved left and right ventricular functions with Trimetazidine in patients with heart failure: A tissue doppler study [J]. Heart Vessels, 2009,24(4) : 277-282.
9Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy [J]. Circulation, 2008,118 (12) : 1250-1258.
10Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of Trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure [Jl. J Am Coil Cardiol, 2006,48 (5) : 992-998.